Guard Therapeutics International Past Earnings Performance
Past criteria checks 0/6
Guard Therapeutics International's earnings have been declining at an average annual rate of -18.1%, while the Biotechs industry saw earnings growing at 17.7% annually.
Key information
-18.1%
Earnings growth rate
61.9%
EPS growth rate
Biotechs Industry Growth | 0.7% |
Revenue growth rate | n/a |
Return on equity | -169.8% |
Net Margin | n/a |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Companies Like Guard Therapeutics International (STO:GUARD) Could Be Quite Risky
Apr 18Guard Therapeutics International (STO:GUARD) Will Have To Spend Its Cash Wisely
Jan 04Here's Why Guard Therapeutics International (STO:GUARD) Must Use Its Cash Wisely
Sep 20Guard Therapeutics International (STO:GUARD) Is In A Good Position To Deliver On Growth Plans
Apr 06We're Keeping An Eye On Guard Therapeutics International's (STO:GUARD) Cash Burn Rate
Sep 09Here's Why We're A Bit Worried About Guard Therapeutics International's (STO:GUARD) Cash Burn Situation
Feb 19We're Not Very Worried About Guard Therapeutics International's (STO:GUARD) Cash Burn Rate
Aug 17Companies Like Guard Therapeutics International (STO:GUARD) Are In A Position To Invest In Growth
Apr 19Here's Why We're Watching Guard Therapeutics International's (STO:GUARD) Cash Burn Situation
Jan 04Revenue & Expenses BreakdownBeta
How Guard Therapeutics International makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 0 | -113 | 9 | 106 |
30 Sep 23 | 0 | -137 | 8 | 131 |
30 Jun 23 | 0 | -146 | 9 | 139 |
31 Mar 23 | 0 | -134 | 9 | 126 |
31 Dec 22 | 0 | -113 | 9 | 105 |
30 Sep 22 | 0 | -95 | 9 | 87 |
30 Jun 22 | 0 | -97 | 7 | 90 |
31 Mar 22 | 0 | -88 | 7 | 80 |
31 Dec 21 | 0 | -82 | 6 | 75 |
30 Sep 21 | 0 | -69 | 5 | 64 |
30 Jun 21 | 0 | -47 | 5 | 42 |
31 Mar 21 | 0 | -44 | 5 | 39 |
31 Dec 20 | 0 | -40 | 5 | 35 |
30 Sep 20 | 0 | -43 | 5 | 37 |
30 Jun 20 | 0 | -39 | 5 | 33 |
31 Mar 20 | 0 | -41 | 6 | 35 |
31 Dec 19 | 0 | -45 | 7 | 38 |
30 Sep 19 | 0 | -73 | 10 | 40 |
30 Jun 19 | 0 | -82 | 11 | 70 |
31 Mar 19 | 0 | -86 | 12 | 73 |
31 Dec 18 | 0 | -87 | 12 | 74 |
30 Sep 18 | 0 | -61 | 10 | 51 |
30 Jun 18 | 0 | -63 | 9 | 54 |
31 Mar 18 | 0 | -67 | 12 | 54 |
31 Dec 17 | 0 | -68 | 12 | 55 |
30 Sep 17 | 0 | -72 | 12 | 62 |
30 Jun 17 | 0 | -68 | 14 | 57 |
31 Mar 17 | 0 | -61 | 10 | 54 |
31 Dec 16 | 0 | -52 | 10 | 45 |
30 Sep 16 | 0 | -43 | 10 | 32 |
30 Jun 16 | 0 | -35 | 10 | 26 |
31 Mar 16 | 0 | -32 | 9 | 23 |
31 Dec 15 | 0 | -30 | 8 | 23 |
30 Sep 15 | 0 | -23 | 6 | 17 |
30 Jun 15 | 0 | -20 | 5 | 15 |
31 Mar 15 | 0 | -15 | 4 | 11 |
31 Dec 14 | 0 | -14 | 4 | 10 |
30 Sep 14 | 2 | -12 | 5 | 8 |
30 Jun 14 | 5 | -9 | 8 | 5 |
31 Mar 14 | 7 | -7 | 11 | 2 |
31 Dec 13 | 8 | -5 | 13 | 0 |
30 Sep 13 | 8 | -4 | 12 | 0 |
30 Jun 13 | 8 | -3 | 11 | 0 |
Quality Earnings: GUARD is currently unprofitable.
Growing Profit Margin: GUARD is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: GUARD is unprofitable, and losses have increased over the past 5 years at a rate of 18.1% per year.
Accelerating Growth: Unable to compare GUARD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GUARD is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).
Return on Equity
High ROE: GUARD has a negative Return on Equity (-169.82%), as it is currently unprofitable.